BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27503648)

  • 1. IMP-27, a Unique Metallo-β-Lactamase Identified in Geographically Distinct Isolates of Proteus mirabilis.
    Dixon N; Fowler RC; Yoshizumi A; Horiyama T; Ishii Y; Harrison L; Geyer CN; Moland ES; Thomson K; Hanson ND
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6418-21. PubMed ID: 27503648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010).
    Hawser SP
    Int J Antimicrob Agents; 2011 Aug; 38(2):186-7. PubMed ID: 21632217
    [No Abstract]   [Full Text] [Related]  

  • 3. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
    Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
    Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
    BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissemination of Multidrug-Resistant Proteus mirabilis Clones Carrying a Novel Integron-Borne
    Ramos AC; Cayô R; Carvalhaes CG; Jové T; da Silva GP; Sancho FMP; Chagas-Neto T; Medeiros EAS; Gales AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular epidemiology of clinical Pseudomonas aeruginosa isolates carrying IMP-1 metallo-beta-lactamase gene in a University Hospital in Turkey.
    Ozgumus OB; Caylan R; Tosun I; Sandalli C; Aydin K; Koksal I
    Microb Drug Resist; 2007; 13(3):191-8. PubMed ID: 17949306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase.
    Tsakris A; Ikonomidis A; Poulou A; Spanakis N; Pournaras S; Markou F
    J Antimicrob Chemother; 2007 Jul; 60(1):136-9. PubMed ID: 17491004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal outbreak caused by VIM-4-producing Proteus mirabilis in a Greek tertiary-care hospital.
    Protonotariou E; Poulou A; Politi L; Meletis G; Chatzopoulou F; Malousi A; Metallidis S; Tsakris A; Skoura L
    Int J Antimicrob Agents; 2020 Aug; 56(2):106060. PubMed ID: 32574790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of Proteus mirabilis carrying the bla metallo-beta-lactamase gene.
    Vourli S; Tsorlini H; Katsifa H; Polemis M; Tzouvelekis LS; Kontodimou A; Vatopoulos AC
    Clin Microbiol Infect; 2006 Jul; 12(7):691-4. PubMed ID: 16774572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging extended-spectrum beta-lactamases in Proteus mirabilis.
    Pagani L; Migliavacca R; Pallecchi L; Matti C; Giacobone E; Amicosante G; Romero E; Rossolini GM
    J Clin Microbiol; 2002 Apr; 40(4):1549-52. PubMed ID: 11923394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrons, β-lactamase and qnr genes in multidrug resistant clinical isolates of Proteus mirabilis and P. vulgaris.
    Mokracka J; Gruszczyńska B; Kaznowski A
    APMIS; 2012 Dec; 120(12):950-8. PubMed ID: 23030307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial Susceptibility and Molecular Epidemiology of
    Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY
    Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of a novel integron-located variant (blaOXA -320 ) of Class D β-lactamase in Proteus mirabilis.
    Cicek AC; Duzgun AO; Saral A; Sandalli C
    J Basic Microbiol; 2014 Oct; 54(10):1030-5. PubMed ID: 24027220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of extensive drug resistance and high prevalence of multidrug resistance among clinical Proteus mirabilis isolates in Egypt.
    ElTaweel M; Said HS; Barwa R
    Ann Clin Microbiol Antimicrob; 2024 May; 23(1):46. PubMed ID: 38790053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristic of resistance to beta-lactam antibiotics of nosocomial strains of Proteus mirabilis].
    Ivanov DV
    Zh Mikrobiol Epidemiol Immunobiol; 2008; (6):75-8. PubMed ID: 19189465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
    Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
    Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
    Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
    J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.